Drug intelligence / Profile preview

pinus sylvestris pollen

Development stage
Unknown
Lead developer
ALK Abelló
Modality
Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Oral, Intradermal, Subcutaneous, Inhalation, Sublingual
01

Overview

Pinus sylvestris pollen, derived from the Scots pine, is utilized in clinical medicine primarily as an allergen extract for the diagnosis and treatment of IgE-mediated allergies. In diagnostic settings, such as skin prick testing, the pollen extract is used to identify sensitization in patients presenting with seasonal respiratory symptoms. In the context of allergen immunotherapy (AIT), also known as allergy vaccination, standardized extracts are administered to induce immunological tolerance, shifting the immune response from a Th2-mediated allergic profile to a Th1/Treg-mediated regulatory profile. Although Pinus sylvestris is generally characterized by lower allergenic potential compared to deciduous trees like birch, it is a relevant allergen in regions with extensive coniferous forests. Beyond its clinical use, Pinus sylvestris pollen is also marketed as a dietary supplement (often simply termed 'pine pollen') for its purported antioxidant, anti-inflammatory, and androgenic properties, though these applications lack the rigorous clinical validation required for pharmaceutical indications.

Brand names
Soluprick
Other names
Scots pine pollenPine pollen
02

Targets

IgE (Immunoglobulin E)

Beyond the preview

Go deeper on pinus sylvestris pollen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on pinus sylvestris pollen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call